Carrie Bourdow
Chief Executive Officer bij TREVENA, INC.
Vermogen: 43 442 $ op 31-03-2024
Profiel
Carrie L.
Bourdow is currently the Chairman, President & Chief Executive Officer at Trevena, Inc. She previously served as an Independent Director at Sesen Bio, Inc. from 2020 to 2023 and at Nabriva Therapeutics Plc from 2017 to 2023.
Prior to that, she was the Vice President-Marketing at Cubist Pharmaceuticals LLC from 2013 to 2015.
Ms. Bourdow holds an undergraduate degree from Hendrix College and an MBA from Southern Illinois University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
TREVENA, INC.
0.51% | 09-02-2024 | 93 214 ( 0.51% ) | 42 878 $ | 31-03-2024 |
NABRIVA THERAPEUTICS PLC
0.01% | 31-01-2023 | 397 ( 0.01% ) | 564 $ | 31-07-2023 |
Actieve functies van Carrie Bourdow
| Bedrijven | Functie | Begin |
|---|---|---|
| TREVENA, INC. | Chief Executive Officer | 01-10-2018 |
Eerdere bekende functies van Carrie Bourdow
| Bedrijven | Functie | Einde |
|---|---|---|
| NABRIVA THERAPEUTICS PLC | Director/Board Member | 30-07-2023 |
| CARISMA THERAPEUTICS, INC. | Director/Board Member | 07-03-2023 |
| CUBIST PHARMACEUTICALS INC | Sales & Marketing | 01-05-2015 |
Opleiding van Carrie Bourdow
| Hendrix College | Undergraduate Degree |
| Southern Illinois University | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| TREVENA, INC. | Health Technology |
| NABRIVA THERAPEUTICS PLC | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
